Will Trump’s America lose out on the next big thing in business? Will Trump’s America lose out on the next big thing in business? Blair Gable/Reuters

US could lose out in budding pot market

Mexico and Canada in a position to benefit from lucrative marijuana industry

The president of the United States, Donald Trump, prides himself on his business acumen. But his protectionism may get America a truly bad deal when it comes to North America’s next big market: marijuana. The Conversation

Fulfilling a campaign promise, on April 13 Canadian Prime Minister Justin Trudeau presented a bill to legalize cannabis for recreational uses (medical marijuana has been legal in the country since 2001).

Two weeks later, Mexico’s Congress followed suit, passing a bill to authorize cannabis use for medical and scientific purposes.

Two of three North American countries are now well positioned to unlock an industry that, according to Forbes magazine, was worth an estimated US $7.2 billion in 2016 and is projected to grow at a compound annual rate of 17%.

In the U.S., on the other hand, a protectionist administration has threatened to withdraw from the “terrible” North American Free Trade Agreement (NAFTA) and actively relaunched the U.S. drug war. It looks like America’s businessman president may allow his country to miss out on the cannabis boom.

Medical marijuana research is a growth industry. Cannabinoids, a main (non-psychoactive) chemical component in marijuana, hold significant prospects for development in the pharmaceutical industry, as potentially does tetrahydrocannabinol (THC), the ingredient that makes users feel high.

Marijuana has been scientifically proven to soothe the effects of chemotherapy, treat glaucoma and ease some chronic pain. But many fields of inquiry remain untapped, thanks in large part to stringent U.S. laws that classify cannabis as a Schedule I drug. That’s the most tightly restricted category, reserved for substances with “no currently accepted medical use.”

Pharmaceutical companies are keen to further disprove that thesis, knowing they will soon be able to patent cannabis-based medicines in both Mexico and Canada. Patients and doctors, too, have pleaded for restrictions on medical marijuana research in the U.S. to be eased.

In the U.S., eight states and Washington, DC, have also legalized recreational marijuana. A total of 29 states plus the nation’s capital have legal medical cannabis.

But U.S. Attorney General Jeff Sessions (who has declared that he “rejects the idea that America will be a better place if marijuana is sold in every corner store”) and Homeland Security chief John Kelly (who has erroneously called marijuana a “dangerous gateway drug”) consistently overlook this fact.

The Trump administration is determined to revamp prohibitionist policies. In a radical rollback of Barack Obama’s compassionate approach to nonviolent drug offenders, Sessions has actually ordered federal prosecutors to charge suspects of any drug-related crime with the “most serious, readily provable offence,” or whichever crime entails the harshest punishment.

This move will have well-documented implications for law enforcement. In 2015, marijuana arrests outweighed those made for all violent crimes combined, including murder and rape, 574,000 to 505,681, according to the NGO Human Rights Watch.

Now America’s drug war will have commercial consequences too. In the U.S., the National Institute on Drug Abuse has developed research mainly on the negative effects of cannabis, only marginally considering its potential medical uses.

Medical trials conducted on human beings require permission from several federal agencies, including the Department of Health and Human Services, the Food and Drug Administration and, when it comes to illegal substances, the Drug Enforcement Administration. That makes getting clearance for cannabis trials unduly complicated.

The inconsistencies between federal and state legislation also discourage research because they do not offer a secure legal ground for patenting cannabis-based medicines. Potential investors in medical cannabis are forced to consider not only corporate competition but also criminal prosecution.

Likewise, because budding American cannabis producers struggle to access investment funding, the industry’s growth potential remains stunted.

If all of this sounds bad for American investors and patients, it’s good news for Mexico and Canada.

The Mexican medical marijuana bill championed by President Enrique Peña Nieto, who is not a bold politician, is quite limited. It emerged in response to the story of Grace, a profoundly epileptic eight-year-old girl for whom cannabis oil, illicitly administered by her desperate mother, proved a literal lifesaver.

By removing from cannabis the legal label of “forbidden plant,” the law will enable it to be used for medical or scientific purposes and permit the health secretariat to conduct clinical research.

In legal terms, Mexican cannabis is now a commercial good that falls under NAFTA’s purview. Medical cannabis is estimated to bring in between $1 billion and $2 billion to Mexico over the next 10 years.

Canada is making a bigger bet on marijuana. Once its cannabis-regulation bill is implemented in July 2018, it will become the second country in the world to fully legalize marijuana, after Uruguay. It will stop short of establishing an open market, though; provinces will decide where and how marijuana may be sold and priced, in conjunction with the federal government.

As in Mexico, Canadian cannabis will comprise a commercial good. Its medical marijuana market is expected to be worth $1 billion by 2020, while recreational marijuana prospects run as high as $22.6 billion.

Once both countries’ systems are up and running, cannabis trading between Mexico and Canada can begin. The world’s first cannabis-focused exchange traded fund has already opened on the Toronto Stock Exchange.

In theory, Canada and Mexico could also trade medical marijuana with dozens of U.S. states. But given the current administration’s “America First” motto, anti-Mexico rhetoric and fear-mongering about drugs, that may prove difficult.

The federal government is also forcing the U.S. to miss out on something more valuable than profit: improving public health and social well-being.

Drugs in general and cannabis, in particular, can do harm if misused. But they are far less dangerous than the drug war itself. After all, the health risks associated with legal cannabis can be prevented by strict packaging and labelling guidelines.

For Canada, which has long been progressive in its drug policy, cannabis legalization should continue to reduce the harm created by the illicit drug trade.

Mexico’s bill has more radical implications for health and public safety. An average of 51 people die every day in the country’s violent drug war. That’s so many homicides that male life expectancy has actually dropped by more than half a year since 2010.

For many Mexicans, the revenue from medical marijuana is less important than the possibility of rolling back the deadly drug war. The country’s timid steps towards legalizing medical marijuana have begun a critical process of democratic deliberation around using the military for law enforcement in the war on drugs.

As for the U.S., it needn’t miss out. If only to keep America from falling behind Canada and Mexico, a scenario that would haunt its president, Trump could take action to improve the health, wealth and safety of his people. And that, to use his own words, would actually be a “fair deal for all.”

Luis Gómez Romero is a senior lecturer in human rights, constitutional law and legal theory at the University of Wollongong, Australia. This article was originally published on The Conversation.

Reader forum